IndiaNifty 5024,295.85▲ +0.19%
IndiaBSE Sensex77,850.62▲ +0.25%
IndiaNifty Bank57,048.05▼ -0.28%
IndiaNifty IT31,607.55▲ +1.56%
IndiaNifty Auto28,039.20▲ +3.47%
IndiaNifty Pharma26,423.80▲ +0.19%
IndiaNifty FMCG49,678.50▲ +1.91%
USS&P 5007,316.15▼ -1.52%
USDow Jones51,594.14▼ -2.19%
USNASDAQ24,442.94▼ -1.74%
UKFTSE 10010,907.68▼ -0.01%
JapanNikkei 22561,867.43▲ +0.71%
Hong KongHang Seng25,873.58▲ +0.25%
GermanyDAX25,402.33▼ -0.23%
FranceCAC 408,458.45▲ +0.60%
AustraliaASX 2008,967.70▼ -0.78%
IndiaNifty 5024,295.85▲ +0.19%
IndiaBSE Sensex77,850.62▲ +0.25%
IndiaNifty Bank57,048.05▼ -0.28%
IndiaNifty IT31,607.55▲ +1.56%
IndiaNifty Auto28,039.20▲ +3.47%
IndiaNifty Pharma26,423.80▲ +0.19%
IndiaNifty FMCG49,678.50▲ +1.91%
USS&P 5007,316.15▼ -1.52%
USDow Jones51,594.14▼ -2.19%
USNASDAQ24,442.94▼ -1.74%
UKFTSE 10010,907.68▼ -0.01%
JapanNikkei 22561,867.43▲ +0.71%
Hong KongHang Seng25,873.58▲ +0.25%
GermanyDAX25,402.33▼ -0.23%
FranceCAC 408,458.45▲ +0.60%
AustraliaASX 2008,967.70▼ -0.78%
Invest and Educate
NYQ · USD

Johnson & Johnson

JNJ
265.53
▼ -1.20 (-0.45%)
Price Chart
6MO · Daily
2026-02-102026-03-102026-04-072026-05-042026-06-012026-06-292026-07-29221.32236.32251.32267.24
Key Ratios & Fundamentals
Market Cap
624.12B
P/E (TTM)
30.11
Fwd P/E
20.20
P/B
7.69
P/S
6.37
Book Value
33.74
EPS (TTM)
8.61
Fwd EPS
12.83
Div Yield
+2.07%
Beta
0.24
ROE
ROA
D/E
67.73
Current Ratio
Profit Margin
+21.48%
Op Margin
+28.61%
52W High
269.43
52W Low
164.23
50D Avg
241.15
200D Avg
224.26
Avg Volume
8.23M
Shares Out
2.41B
Sector
Healthcare
Industry
Drug Manufacturers - General
About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

SWOT Analysis
Auto-derived from fundamentals
Strengths
  • Robust net profit margin of 21.5% — strong pricing power
  • Superior operating margin of 28.6% — strong operational leverage
  • Reasonable dividend yield of 2.07%
  • Low beta of 0.23 — defensive characteristics
  • Large-cap scale — index inclusion, institutional coverage, deep liquidity
Weaknesses
  • No major red flags in reported financials — continue monitoring quarterly results
Opportunities
  • Forward P/E of 20.2x is below trailing — market expects earnings growth
  • Positioned in Healthcare — defensive sector, aligned with respective macro cycles
Threats
  • Trading near 52-week high (90% of range) — limited upside before pullback
  • Extended 16% above 200-day MA — overbought technically
Latest News · Johnson & Johnson
10 stories
The new AI trade: Visa, Shopify, and more
Host Kenny Polcari, Robinhood CIO Stephanie Guild, and Payne Capital Management President Ryan Payne discuss why they believe the AI trade is still alive, and how investors can reduce spending risk by looking beyond hyperscalers and semiconductors.
Yahoo Finance Video·16h ago
Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement
Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants bef
Simply Wall St.·7h ago
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
The Wall Street Journal·9h ago
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
But is that performance sustainable?
Motley Fool·10h ago
Anika Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call
Moby·12h ago
This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets
A $3 million portfolio sounds like enough to retire on, but the math gets uncomfortable fast when you need $18,000 a month and a single income strategy quietly destroys the principal it was supposed to protect.
24/7 Wall St.·12h ago
The Real Price of AbbVie Stock Is Cheaper Than You Think
The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.
Trefis·13h ago
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.
Zacks·15h ago
Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device
Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c
MT Newswires·16h ago
The Best House On The Block Costs The Most: ISRG
In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.
Trefis·17h ago
Invest & Educate · Data: Yahoo Finance · News: ET · Mint · Moneycontrol
PrivacyTermsEducational use only. Not investment advice.